New common variants affecting susceptibility to basal cell carcinoma In a follow-up to our previously reported genome-wide association study of cutaneous basal cell carcinoma (BCC) 1 , we describe here several new susceptibility variants. SNP rs11170164, encoding a G138E substitution in the keratin 5 ( KRT5 ) gene, affects risk of BCC (OR = 1.35, P = 2.1 × 10?9). A variant at 9p21 near CDKN2A and CDKN2B also confers susceptibility to BCC (rs2151280[C]; OR = 1.19, P = 6.9 × 10?9), as does rs157935[T] at 7q32 near the imprinted gene KLF14 (OR = 1.23, P = 5.7 × 10?10). The effect of rs157935[T] is dependent on the parental origin of the risk allele. None of these variants were found to be associated with melanoma or fair-pigmentation traits. A melanoma- and pigmentation-associated variant in the SLC45A2 gene, L374F, is associated with risk of both BCC and squamous cell carcinoma. Finally, we report conclusive evidence that rs401681[C] in the TERT - CLPTM1L locus confers susceptibility to BCC but protects against melanoma.  METHODS Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/ .  Supplementary Material Stacy 2009 Online Methods  Figure and Tables Figure 1 Schematic view of the LD structure of the 9p21 CDKN2A/B region, locations of relevant genes and genome-wide association data for BCC and coronary artery disease (CAD). ( a ) Pairwise correlation structure of a 300-kb interval from 21.9 Mb to 22.2 Mb (NCBI Build 36) on 9p21. The upper plot (blue) shows the pairwise D ? values for SNPs with minor allele frequencies >5% from the HapMap v22 CEU dataset. The lower plot shows the corresponding r 2 values. ( b ) Estimated recombination rates (saRR) in cM/Mb from the HapMap Phase II data. ( c ) Location of RefSeq genes and the ANRIL transcript. ( d ) Locations of the SNPs giving the most significant signals for BCC, CAD and T2D. ( e ) Illumina chipderived genome-wide association data for BCC (red dots) and CAD (blue dots). Note that the overall most significant CAD SNP rs10757278 is not represented on the Illumina chip but is highly correlated with rs10116277 ( D ? = 0.96, r 2 = 0.90 in HapMap CEU). Table 1 Association of SNPs in KRT5 and the 9p21 and 7q32 loci with BCC, SCC and CM SNP Allele Locus Sample group Number Frequency OR 95% CI P P het a Cases Controls Cases Controls rs11170164 A KRT5 (G138E) Iceland BCC 1,833 34,845 0.109 0.086 1.29 (1.14, 1.46) 4.4 × 105 Eastern Europe BCC 525 532 0.122 0.073 1.75 (1.31, 2.35) 1.6 × 10?4 US BCC 930 849 0.097 0.071 1.40 (1.10, 1.77) 6.1 × 10?3 Spain BCC 185 1,689 0.065 0.052 1.28 (0.81, 2.01) 0.29 All non-Icelandic BCC 1,640 3,070 NA NA 1.49 (1.26, 1.77) 4.6 × 10 ?6 0.38 All BCC combined 3,473 37,915 NA NA 1.35 (1.23, 1.50) 2.1 × 10 ?9 0.29 Iceland SCC b 434 34,845 0.111 0.086 1.31 (1.05, 1.64) 1.8 × 10?2 US SCC 710 849 0.082 0.071 1.16 (0.89, 1.51) 0.27 All SCC combined 1,144 35,694 NA NA 1.25 (1.05, 1.48) 1.2 × 10 ?2 0.49 All CM c combined 3,932 39,643 NA NA 1.03 (0.92, 1.15) 0.58 0.11 rs2151280 C 9p21 CDKN2A/B Iceland BCC 1,831 34,998 0.581 0.531 1.22 (1.13, 1.31) 7.6 × 10?8 Eastern Europe BCC 525 524 0.548 0.517 1.13 (0.95, 1.34) 0.16 US BCC 871 826 0.537 0.505 1.13 (0.99, 1.30) 6.8 × 10?2 Spain BCC 185 1,687 0.514 0.486 1.12 (0.90, 1.38) 0.32 All non-Icelandic BCC 1,581 3,037 NA NA 1.13 (1.03, 1.24) 1.2 × 10 ?2 0.99 All BCC combined 3,412 38,035 NA NA 1.19 (1.12, 1.26) 6.9 × 10 ?9 0.65 Iceland SCC b 437 34,998 0.534 0.531 1.01 (0.90, 1.13) 0.87 US SCC 642 826 0.532 0.505 1.11 (0.96, 1.29) 0.15 All SCC combined 1,079 35,824 NA NA 1.05 (0.96, 1.15) 0.31 0.31 All CM c combined 3,897 39,779 NA NA 1.01 (0.95, 1.07) 0.74 0.88 rs157935 T 7q32 Iceland BCC 1,832 34,963 0.722 0.675 1.25 (1.15, 1.35) 3.6 × 10?8 Eastern Europe BCC 526 530 0.723 0.693 1.16 (0.96, 1.40) 0.13 US BCC d 723 611 0.740 0.691 1.27 (1.07, 1.50) 5.6 × 10?3 Spain BCC 183 1,703 0.730 0.718 1.06 (0.83, 1.35) 0.63 All non-Icelandic BCC 1,432 2,844 NA NA 1.18 (1.06, 1.32) 3.2 × 10 ?3 0.47 All BCC Combined 3,264 37,807 NA NA 1.23 (1.15, 1.31) 5.7 × 10 ?10 0.55 Iceland SCC b 433 34,963 0.666 0.675 0.96 (0.79, 1.17) 0.66 US SCC d 513 611 0.712 0.691 1.11 (0.92, 1.34) 0.28 All SCC combined 946 35,574 NA NA 1.03 (0.90, 1.18) 0.63 0.29 All CM c combined 3,921 39,770 NA NA 1.00 (0.94, 1.06) 0.94 0.35 BCC paternal allele e 1,118 f 34,869 g 0.745 0.676 1.40 (1.22, 1.60) 1.5 × 10?6 BCC maternal allele e 1,118 f 34,869 g 0.694 0.675 1.09 (0.96, 1.25) 0.18 BCC, cutaneous basal cell carcinoma. SCC, cutaneous squamous cell carcinoma. CM, cutaneous melanoma (malignant or in situ ). a I value for heterogeneity. b Cases diagnosed with SCC without BCC. c Contributing CM sample groups (and approximate numbers) were from Iceland (589 cases, 34,998 controls), Holland (749 cases, 1,831 controls), Sweden (1,065 cases, 540 controls), Austria (152 cases, 376 controls), Spain (816 cases, 1,703 controls) and Italy (564 cases, 368 controls). d SNP rs157935 could not be typed in the US BCC and SCC samples so a surrogate SNP, rs125124, was used ( r 2 = 1.0 in HapMap CEU). Frequency and OR are given for the rs125124[C] allele. e Analysis based on Icelandic cases and controls who were typed by an Illumina chip and for whom the Icelandic genealogy and long-range phasing haplotypes were used to determine parental origins of alleles. f Number of paternal/maternal alleles examined in cases. g Number of paternal/maternal alleles examined in controls. Table 2 KRT5 rs641615 D197E is associated with BCC independently of rs11170164 G138E Sample group Number Frequency rs641615[C] a unadjusted rs641615[C] adjusted for rs11170164 Cases Controls Cases Controls OR 95% CI P OR Residual P Iceland BCC 1,674 2,462 0.79 0.76 1.17 (1.05, 1.30) 3.8 × 10?3 1.13 3.5 × 10?2 Eastern Europe BCC 528 532 0.77 0.72 1.31 (1.08, 1.60) 6.9 × 10?3 1.24 3.7 × 10?2 Spain BCC 182 1,687 0.76 0.71 1.26 (0.99, 1.62) 6.2 × 10?2 1.24 8.7 × 10?3 All BCC combined b 2,384 4,681 NA NA 1.21 (1.11, 1.32) 2.2 × 10 ?5 1.17 1.0 × 10 ?3 a Note that increased BCC risk is associated with the reference (Asp) allele of the D197E substitution encoded by rs641615. b P het = 0.55 for unadjusted ORs. Table 3 Association of SLC45A2 L374F rs16891982[G] with BCC, SCC and CM Sample group Number Frequency OR 95% CI P P het Cases Controls Cases Controls Iceland BCC 1,690 2,456 0.987 0.982 1.38 (0.97, 1.96) 7.3 × 10?2 US BCC 927 843 0.984 0.953 2.99 (2.00, 4.47) 8.9 × 10?8 Eastern Europe BCC 523 522 0.967 0.945 1.67 (1.09, 2.55) 1.8 × 10?2 Spain BCC 186 1,672 0.917 0.829 2.27 (1.61, 3.20) 3.0 × 10?6 All BCC combined 3,326 5,493 NA NA 1.97 (1.63, 2.38) 1.6 × 10 ?12 0.026 Iceland SCC b 420 2,456 0.992 0.982 2.22 (1.11, 4.42) 2.3 × 10?2 US SCC 699 843 0.984 0.953 2.94 (1.90, 4.54) 1.2 × 10?6 All SCC combined 1,119 3,299 NA NA 2.71 (1.88, 3.92) 1.0 × 10 ?7 0.5 Iceland CM 555 2,456 0.988 0.982 1.58 (0.90, 2.76) 0.11 Holland CM 747 1,777 0.990 0.975 2.56 (1.56, 4.20) 2.0 × 10?4 Sweden CM 1,061 541 0.988 0.957 3.58 (2.23, 5.75) 1.4 × 10?7 Austria CM 152 376 0.984 0.964 2.23 (0.92, 5.42) 7.7 × 10?2 Italy CM 560 367 0.949 0.900 2.06 (1.44, 2.95) 7.7 × 10?5 Spain CM 805 1,672 0.935 0.829 (2.42, 3.60) 2.95 8.5 × 10?27 All CM combined 3,880 7,189 NA NA 2.95 (2.42, 3.60) 8.3 × 10 ?39 0.15 a Note that increased risk is associated with the reference (Leu) allele of the L374F variant encoded by rs16891982. b Cases diagnosed with SCC without BCC. Table 4 Association of TERT-CLPTM1L rs401681 with BCC, SCC and CM Sample group Risk allele Number Frequency OR 95% CI P P het Cases Controls Cases Controls Iceland BCC a C 1,850 34,998 b 0.60 0.55 1.23 (1.14, 1.33) 6.0 × 10?8 Eastern Europe BCC a C 525 525 0.62 0.57 1.19 (1.00, 1.42) 4.5 × 10?2 US BCC C 908 826 0.59 0.56 1.12 (0.98, 1.28) 0.10 Spain BCC C 185 1,758 0.55 0.54 1.08 (0.86, 1.35) 0.50 All non-Icelandic BCC C 1,618 3,109 NA NA 1.13 (1.03, 1.25) 1.1 × 10 ?2 0.74 All BCC combined C 3,468 38,107 NA NA 1.20 (1.13, 1.27) 4.8 × 10 ?9 0.53 Iceland SCC a C 438 34,998 b 0.57 0.55 1.08 (0.94, 1.24) 0.28 US SCC C 665 826 0.57 0.56 1.01 (0.87, 1.17) 0.92 All SCC combined C 1,103 35,824 NA NA 1.04 (0.94, 1.16) 0.39 0.51 Iceland CM a C 591 34,998 b 0.52 0.55 0.90 (0.80, 1.01) 7.9 × 10?2 Sweden CM a C 1,056 2,631 0.49 0.54 0.85 (0.77, 0.94) 1.2 × 10?3 Spain CM a C 748 1,758 0.51 0.54 0.90 (0.80, 1.02) 9.4 × 10?2 Holland CM C 736 1,832 0.53 0.57 0.83 (0.73, 0.94) 3.9 × 10?3 Austria CM C 152 376 0.53 0.53 0.98 (0.75, 1.27) 0.88 Italy CM C 560 368 0.49 0.56 0.74 (0.62, 0.89) 1.2 × 10?3 All new CM c C 1,448 2,576 NA NA 0.83 (0.76, 0.91) 9.4 × 10 ?5 0.21 All CM combined C 3,843 41,963 NA NA 0.86 (0.81, 0.91) 5.0 × 10 ?8 0.41 a Updated data from Rafnar et al. 4 b Skin cancer-free controls. c Combined CM data from Holland, Austria and Italy. 